Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Sponsor: Gilead Sciences
Terminated
Sponsor's decision to discontinue development of entospletinib.
Other terminated trials from Gilead Sciences
Other Chronic Lymphocytic Leukemia trials with similar outcome
This PHASE2 trial investigates Chronic Lymphocytic Leukemia and Diffuse Large B-cell Lymphoma and is currently terminated or withdrawn. Gilead Sciences leads this study, which shows 18 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
18 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 13 earlier versions
-
Oct 2020 — Dec 2020 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Mar 2020 — Oct 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
Oct 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
Mar 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .